The overarching goal of the Administrative Core is to oversee and coordinate all scientific, regulatory, administrative and fiscal responsibilities of the Program Project grant. The Administrative Core will accomplish its goal through the following specific aims: 1. Ensure integration of all Projects and Cores by managing all oversight strategies, including coordinating the meetings and the External and Internal Advisory Committees and implementing the recommendations of these Committees. 2. Authority to realign resources based upon advice from the External and Internal Advisory Committees in collaboration with the Executive Committee (Program Leaders and Project/Core Leaders). 3. Administer and implement the multiple Principal Investigator Plan. 4. Organize the monthly meetings of the Executive Committee, biannual meeting of Internal Advisory Committee and fri-annual meeting of External Advisory Committee. Organize the POl yearly retreat to assess overall P01 progress, based upon quantitative milestones, and plan and implement next steps making use of the reports from the Internal and External Advisory Committees. 5. Provide fiscal accountability via coordination with Institutional and NCI staff. 6. Document productivity of all Projects and Cores, as defined by discrete endpoints such as manuscripts, filed provisional patent applications, and invited lectures. 7. Prepare all progress reports and responses to External and Internal Advisory Committees. 8. Coordinate and oversee all scientific, regulatory, administrative and fiscal interactions between The John Wayne Cancer Institute, Memorial Sloan-Kettering Cancer Center, Mt Sinai Medical Center, The Jackson Laboratory and Penn State University. 9. Provide oversight management to ensure that biostatistics analyses and plans are implemented for all Projects and Cores. 10. Coordinate Data Sharing modalities between Institutions, NIH, NCL and the public. 11. Coordinate the monthly Core presentations to the Executive Committee that will include description of the active and pending requests for support from each Project.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Pennsylvania State University
United States
Zip Code
Shaw, Jeremy; Costa-Pinheiro, Pedro; Patterson, Logan et al. (2018) Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era. Adv Cancer Res 140:327-366
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Verma, Mohit K; Clemens, Julia; Burzenski, Lisa et al. (2017) A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods 446:47-53
Olson, Kristine C; Kulling, Paige M; Olson, Thomas L et al. (2017) Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. Cancer Biol Ther 18:290-303
Hengst, Jeremy A; Dick, Taryn E; Sharma, Arati et al. (2017) SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models. Cancer Transl Med 3:109-121
Morad, Samy A F; Davis, Traci S; MacDougall, Matthew R et al. (2017) Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. Biochem Pharmacol 130:21-33
Doshi, Ushma A; Shaw, Jeremy; Fox, Todd E et al. (2017) STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. Signal Transduct Target Ther 2:17051
Tan, Su-Fern; Pearson, Jennifer M; Feith, David J et al. (2017) The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. Expert Opin Ther Targets 21:583-590
Linton, Samuel S; Sherwood, Samantha G; Drews, Kelly C et al. (2016) Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:208-22
Tan, Su-Fern; Liu, Xin; Fox, Todd E et al. (2016) Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget 7:83208-83222

Showing the most recent 10 out of 27 publications